Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
- Gene therapy program VTX-806 demonstrated normalization of toxic bile acid
metabolites in blood, liver, tendons and brain in a CTX mouse model for the first time,
holding promise for curative treatment - Long term characterization of B6.129-Cyp27a1tmlEl t/J CTX mouse model showed
measurable motor alterations similar to those described in CTX patients validating
model for translation
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech
company developing novel and long-lasting gene therapies for rare inherited liver metabolic
disorders, today announces that it will be presenting key pre-clinical findings for VTX-806, its
gene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at The
Liver Meeting presented by the American Association for the Study of Liver Diseases (AASLD),
being held in San Diego, CA from 15-19 November.
